These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21994454)

  • 1. Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies.
    Terajima M; Cruz J; Co MD; Lee JH; Kaur K; Wrammert J; Wilson PC; Ennis FA
    J Virol; 2011 Dec; 85(24):13463-7. PubMed ID: 21994454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection.
    Sakabe S; Iwatsuki-Horimoto K; Horimoto T; Nidom CA; Le Mt; Takano R; Kubota-Koketsu R; Okuno Y; Ozawa M; Kawaoka Y
    Antiviral Res; 2010 Dec; 88(3):249-55. PubMed ID: 20849879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monoclonal antibodies with high virus-neutralizing activity against pandemic influenza virus A/llV-Moscow/01/2009 (H1N1)swl].
    Klimova RR; Masalova OV; Burtseva EI; Chichev EV; Lesnova EI; Oskerko TA; Mukasheva EA; Rudneva IA; Lvov DK; Kushch AA
    Vopr Virusol; 2011; 56(3):15-20. PubMed ID: 21786621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterization of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009).
    Cabral TM; Berhane Y; Schmidt L; Tracz DM; Hole K; Leith M; Corbett CR
    J Virol Methods; 2012 Jul; 183(1):25-33. PubMed ID: 22575685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009) using plasmid DNA immunogen.
    Cabral TM; Baig A; Berhane Y; Schmidt L; Hole K; Leith M; Kobasa D; Corbett CR
    J Virol Methods; 2014 Jan; 195():54-62. PubMed ID: 24060631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.
    Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.
    Throsby M; van den Brink E; Jongeneelen M; Poon LL; Alard P; Cornelissen L; Bakker A; Cox F; van Deventer E; Guan Y; Cinatl J; ter Meulen J; Lasters I; Carsetti R; Peiris M; de Kruif J; Goudsmit J
    PLoS One; 2008; 3(12):e3942. PubMed ID: 19079604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of a panel of cross-reactive monoclonal antibodies generated using H1N1 influenza virus.
    Guo CY; Tang YG; Qi ZL; Liu Y; Zhao XR; Huo XP; Li Y; Feng Q; Zhao PH; Wang X; Li Y; Wang HF; Hu J; Zhang XJ
    Immunobiology; 2015 Aug; 220(8):941-6. PubMed ID: 25708705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies.
    Du L; Zhao G; Zhang X; Liu Z; Yu H; Zheng BJ; Zhou Y; Jiang S
    Biochem Biophys Res Commun; 2010 Jul; 397(3):580-5. PubMed ID: 20617558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
    Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization and Binding Profile of Monoclonal Antibodies Generated Against Influenza A H1N1 Viruses.
    Shembekar N; Mallajosyula VV; Malik A; Saini A; Varadarajan R; Gupta SK
    Monoclon Antib Immunodiagn Immunother; 2016 Aug; 35(4):191-8. PubMed ID: 27463230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fully human broadly neutralizing monoclonal antibodies against influenza A viruses generated from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient.
    Hu W; Chen A; Miao Y; Xia S; Ling Z; Xu K; Wang T; Xu Y; Cui J; Wu H; Hu G; Tian L; Wang L; Shu Y; Ma X; Xu B; Zhang J; Lin X; Bian C; Sun B
    Virology; 2013 Jan; 435(2):320-8. PubMed ID: 23084424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
    Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
    Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An H1N1 Computationally Optimized Broadly Reactive Antigen Elicits a Neutralizing Antibody Response against an Emerging Human-Infecting Eurasian Avian-Like Swine Influenza Virus.
    Sautto GA; Ecker JW; Ross TM
    J Virol; 2021 Jun; 95(13):e0242120. PubMed ID: 33853960
    [No Abstract]   [Full Text] [Related]  

  • 16. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.
    Li GM; Chiu C; Wrammert J; McCausland M; Andrews SF; Zheng NY; Lee JH; Huang M; Qu X; Edupuganti S; Mulligan M; Das SR; Yewdell JW; Mehta AK; Wilson PC; Ahmed R
    Proc Natl Acad Sci U S A; 2012 Jun; 109(23):9047-52. PubMed ID: 22615367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of neutralizing efficacy of monoclonal antibodies specific for 2009 pandemic H1N1 influenza A virus in vitro and in vivo.
    Chen J; Yan B; Chen Q; Yao Y; Wang H; Liu Q; Zhang S; Wang H; Chen Z
    Arch Virol; 2014 Mar; 159(3):471-83. PubMed ID: 24057757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Computationally Optimized Broadly Reactive Antigen Subtype-Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against Hemagglutinin.
    Sautto GA; Kirchenbaum GA; Abreu RB; Ecker JW; Pierce SR; Kleanthous H; Ross TM
    J Immunol; 2020 Jan; 204(2):375-385. PubMed ID: 31811019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children.
    Co MD; Terajima M; Thomas SJ; Jarman RG; Rungrojcharoenkit K; Fernandez S; Yoon IK; Buddhari D; Cruz J; Ennis FA
    Viral Immunol; 2014 Oct; 27(8):375-82. PubMed ID: 25141276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies.
    Kashyap AK; Steel J; Oner AF; Dillon MA; Swale RE; Wall KM; Perry KJ; Faynboym A; Ilhan M; Horowitz M; Horowitz L; Palese P; Bhatt RR; Lerner RA
    Proc Natl Acad Sci U S A; 2008 Apr; 105(16):5986-91. PubMed ID: 18413603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.